[ad_1]
Bristol-Myers Squibb Co.
BMY, + 0.02%
On Friday, a late-stage trial of a small-cell lung cancer treatment did not achieve its primary goal. The pharmaceutical company said that the Phase 3 trial called CheckMate-331 evaluating opdivo in patients with recurrent disease following platinum-based chemotherapy did not meet its primary endpoint of overall survival. "Small cell lung cancer is a very aggressive disease in which there is still an unmet need," said Sabine Maier, Head of Development, Thoracic Cancers, Bristol-Myers Squibb. "We are focusing on finding innovative treatments in oncology to improve outcomes in lung cancer patients." Shares were slightly higher before marketing, but fell by 6.1% in 2018, while the S & P 500 index
SPX, + 1.42%
gained 2.1%.
Have the latest news sent to your inbox. Subscribe to free e-mails from the MarketWatch newsletter. Register here.
Source link
